Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olvi-Vec combined with platinum-etoposide in platinum-resistant/refractory SCLC
NCT07136285Phase 2Recruiting
- Sponsor
- Newsoara Biopharma
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Oncolytic Viruses, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of olvimulogene nanivacirepvec in small cell lung cancer (SCLC), sponsored by Newsoara Biopharma. Started Jul 2023; status: recruiting.
02
Drugs
olvimulogene nanivacirepvec
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07136285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07136285.